TLRY · Tilray Brands, Inc. · Stock research

Current Thesis

The event that justified owning TLRY has come and gone without producing an event. The DEA's expedited rescheduling hearing opened 2026-06-29 and closed 2026-07-15, and Chief ALJ Derek Julius adjourned it not with a recommendation but with a briefing schedule: post-hearing briefs of up to 50 pages due 2026-08-17, after which he will write a recommendation on no stated timeline, with the final call resting with the DEA Administrator. Broad adult-use Schedule III is now a multi-month administrative process with a litigation tail, not a dated catalyst. Price behaved accordingly TLRY printed a fresh 52-week low of $4.20 on 2026-07-08 and has traded $4.35–4.38 since, below the 200-day, with TD Cowen cutting its target to $5 from $7 on 2026-07-14 while keeping a Buy. What remains is a $1.2B-annualized beverage-and-cannabis conglomerate with one genuinely growing leg (international medical) reporting Q4/FY2026 after the close on 2026-07-28 against a consensus of roughly -$0.01. That is an earnings print, not a reform trade, and the calendar is inside the window where fresh positioning is a coin flip.

Bullish and bearish views on Tilray Brands, Inc.

The model's bull view on Tilray Brands, Inc. (TLRY), in brief: International cannabis is the only accelerating leg and it is accelerating hard: Q3 FY2026 (reported ~2026-04-01) showed international cannabis +70% YoY on German legalization volumes, inside record net revenue of $206.7M (+11%) and gross profit of $55M (+6%). The bear view: The hearing produced a briefing calendar, not a decision. Both cases follow in full.

Bull Case

• International cannabis is the only accelerating leg and it is accelerating hard: Q3 FY2026 (reported ~2026-04-01) showed international cannabis +70% YoY on German legalization volumes, inside record net revenue of $206.7M (+11%) and gross profit of $55M (+6%). (Q3 FY2026 release)
• Geographic expansion continues without needing US reform: Tilray Medical launched its first medical cannabis product in Panama on 2026-07-09, extending the medical footprint into Latin America.
• Management reaffirmed FY2026 adjusted EBITDA guidance of $62–72M at the Q3 print a company generating positive adjusted EBITDA rather than a pure cash-burn LP.
• BrewDog adds roughly $200M of annual net revenue and $6–8M of FY2027 adjusted EBITDA, lifting global consolidated net revenue to ~$1.2B annualized and giving the platform a non-cannabis cash contributor.
• The hemp cleanup is still coming: the Continuing Appropriations Act signed 2025-11-12 recriminalizes most intoxicating hemp-derived THC effective ~2026-11-12, with the U.S. Hemp Roundtable estimating ~95% of current hemp-cannabinoid products swept out removing the gray-market undercut on licensed product.
• The 2026-04-23 DOJ Final Order already moved FDA-approved cannabis drugs and state-licensed medical marijuana to Schedule III, with the registration window closing 2026-06-22. The administration has demonstrated it will act, which keeps the broader outcome live rather than theoretical.
• Sell-side has not capitulated: consensus target sits around $6.33 versus a $4.35 tape, and TD Cowen held its Buy through the target cut.

Bear Case

• The hearing produced a briefing calendar, not a decision. Briefs are due 2026-08-17, the ALJ set no date for his recommendation, and the DEA Administrator holds the final pen with the losing side's litigation option intact. The date that anchored the trade is spent.
• Price made a new 52-week low on 2026-07-08 at $4.20, during the hearing itself. A market that will not bid a name while its bullish catalyst is being heard in open session is telling the operator what it thinks of the outcome.
• Shares lost roughly 11% over the trailing month against a Medical-sector gain of ~4.3% and an S&P 500 gain of ~1.3% underperformance into the catalyst, not accumulation.
• TD Cowen's 2026-07-14 target cut to $5 from $7 is a 29% haircut on a maintained Buy. Estimates are being marked down toward the tape, not the tape toward estimates.
• Reform beta is structurally diluted. With BrewDog folded in, cannabis is roughly 31% of consolidated revenue; a favorable Schedule III outcome moves less than a third of the P&L, while the beverage business carries its own margin problems.
• The round trip from ~$5 to ~$23 and back to ~$4 leaves overhead supply stacked at every level a recovery would have to clear, and reliably converts each reform headline into a distribution event.
• Q4/FY2026 lands 2026-07-28 after the close with consensus near -$0.01, a ~105% swing from the year-ago quarter. Dilution is ongoing the Lyphe Group acquisition was funded with ~1.6M new shares in early June 2026 alongside a debt-for-equity retirement of $6M of 2027 converts.

Setup & Price Structure

The structure is broken and has been for months. TLRY trades ~$4.35–4.38 as of 2026-07-16, below the 200-day SMA, having set a new 52-week low at $4.20 on 2026-07-08 the prior $4.50 shelf that the April hearing low defended is gone. There is no higher low, no base, and no reclaim attempt to lean on. Every technical requirement for a momentum entry is unmet: the name needs a daily close back above the ~$5.80–6.00 area to put the 200-day back in play, which is 33–38% away. Between here and there sits the consensus target of $6.33 and TD Cowen's freshly cut $5, both above spot, which is the ordinary condition for a value trap rather than evidence of upside. A long from these levels is a bet that a 52-week-low print eight trading days before an earnings release marks the bottom.

Catalyst Calendar (next 30 days)

• 2026-07-28 (confirmed, after close) Q4 and full-year FY2026 results for the period ended 2026-05-31; conference call 4:30 PM ET. Consensus EPS ~-$0.01. Key lines: whether FY adjusted EBITDA lands inside the reaffirmed $62–72M band, international cannabis growth versus the +70% Q3 comp, and first hard BrewDog contribution detail.
• 2026-07-28 → 2026-07-29 FY2027 guidance, the first framing of the ~$1.2B annualized consolidated revenue base and the $6–8M BrewDog adjusted-EBITDA contribution.
• 2026-08-17 (confirmed) Post-hearing briefs due in the DEA rescheduling proceeding, 50-page cap, closing arguments included. This is a filing deadline, not a ruling; the ALJ recommendation follows on no announced schedule.
• No dated decision point exists between now and the ALJ recommendation. Any move on rescheduling headlines in this window is sentiment, not resolution.

What Would Change Our Mind

A daily close above $5.00 — that reclaims the TD Cowen target level would be the first structural evidence in months, and a sustained daily close above $6.00 would put the 200-day back in play and turn this from a falling knife into an actual setup. Fundamentally, a Q4 print on 2026-07-28 that holds international cannabis growth near the +70% Q3 pace while landing FY adjusted EBITDA at the top of the $62–72M band and guides FY2027 above the ~$1.2B annualized run-rate would argue the operating business is compounding independent of Washington. On the policy side, an ALJ recommendation explicitly endorsing broad adult-use Schedule III, arriving before the hemp recriminalization date of ~2026-11-12, would restore the reform leg that the 2026-07-15 adjournment removed. Absent any of those, the name is a pass and the correct behavior on weakness is to stand aside, not to accumulate.

Correlation Notes

• Trades as high-beta expression of the US cannabis-reform complex alongside CGC, CRON, ACB and the MSOS basket; single-name work is largely wasted because reform headlines move the group in lockstep.
• Peer read-through is negative on quality: Canopy's FY2026 print (2026-06-15) paired strong volume growth Q4 international cannabis +68%, Canada medical +27% YoY, FY net revenue +6% to C$284.6M with a -$0.06 EPS miss on $71.2M Q4 revenue. The sector grows revenue and still bleeds.
• Roughly 31% cannabis revenue mix means TLRY now correlates meaningfully to craft-beverage volumes and European medical distribution, which mutes the reform-beta the group is bought for. On a genuine rescheduling headline, purer US-exposed names should outrun it.
• German medical cannabis volumes are the one exposure uncorrelated to US federal policy, and the Panama launch (2026-07-09) extends that decoupling.
• The ~2026-11-12 hemp recriminalization date is a shared sector catalyst affecting all licensed operators; H.R. 7024 deferring it to 2028 would be a group-wide negative.